Role of Senescence in the Development of Endometrial Cancer

CHU de Reims140 enrolled

Overview

Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...). A study has already been carried out at the Reims University Hospital with inclusion of patients with endometrial cancer and patients with endometrial hyperplasia. It identified specific alterations of nosologic continuum of pathology and characterize areas of interest on the genome.

make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia and endometrial cancers.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

140

Conditions

Endometrial Hyperplasia and Endometrial Cancers

Interventions

Genetic analysisGENETIC

Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient with endometrial hyperplasia or endometrial cancer * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program * patient older than 18 years Exclusion Criteria: \- patient with neoadjuvant chemotherapy or radiotherapy prior to surgery

Locations (1)

Damien JOLLY

Reims, France

RECRUITING

Outcomes

Primary Outcomes

Genetic imbalances

Genetic aberrations detected by comparative genomic hybridization (CGH arry)

Time frame: Day 0

Central Contacts

Emilie RAIMOND

CONTACT

0326789598 eraimond@chu-reims.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.